NCT07772180

Brief Summary

This prospective, non-randomised, pre-post feasibility study evaluates CHANGE, a novel 8-session modularized cognitive behavioral group psychotherapy for young adults (18-25 years) with psychiatric disorders receiving inpatient or day-care treatment. All eligible participants (planned n=30) receive the intervention in addition to treatment-as-usual; there is no control arm. The primary aim is to assess feasibility, acceptability and appropriateness of the intervention (SMI (a German scale for feasibility), SAI (a German scale for acceptability), AIS (a German scale for appropriateness) scales; recruitment, retention, adherence and dropout rates). Secondary outcomes include perceived competence, self-efficacy (SWE), motivation (FEVER), satisfaction, quality of life (WHOQOL-BREF) and level of functioning (GAF), assessed before (T0) and after (T1) the intervention.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
8mo left

Started Sep 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress12%
Sep 2026Jun 2027

First Submitted

Initial submission to the registry

August 11, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 19, 2026

Completed
15 days until next milestone

Study Start

First participant enrolled

September 3, 2026

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2027

Last Updated

August 19, 2026

Status Verified

August 1, 2026

Enrollment Period

9 months

First QC Date

August 11, 2026

Last Update Submit

August 14, 2026

Conditions

Keywords

Young adultstransitional psychiatrygroup psychotherapyfeasibility studypsychoeducationsuicidalitymedia/internet/gaming addictioncommunication skillsself-efficacy

Outcome Measures

Primary Outcomes (8)

  • Feasibility of CHANGE group therapy programme, measured by adapted SMI (a German scale for feasibility, Weiner et al. 2017)

    Questionnaire, consisting originally of 4 items, rated on a 5-point Likert scale, ranging from 1 (completely disagree) to 5 (completely agree), item 5 was added.

    T1 (8 weeks after baseline)

  • Acceptability of CHANGE group therapy programme, measured by SAI (a German version of AIM (Acceptability of intervention) questionnaire, Weiner et al. 2017)

    Questionnaire, consisting originally of 4 items, rated on a 5-point Likert scale, ranging from 1 (completely disagree) to 5 (completely agree), item 5 was added.

    T1 (8 weeks after baseline)

  • Appropriateness of CHANGE group therapy programme, measured by AIS (a German version of IAM (Appropriateness of intervention) questionnaire, Weiner et al. 2017)

    Questionnaire, consisting originally of 4 items, rated on a 5-point Likert scale, ranging from 1 (completely disagree) to 5 (completely agree).

    T1 (8 weeks after baseline)

  • Recruitment rate

    number of consented participants / number of eligible patients

    T1 (8 weeks after baseline)

  • Retention rate

    number of participants completed post-assessment / number of consented participants

    T1 (8 weeks after baseline)

  • Adherence rate

    number of attended sessions / total number of sessions

    T1 (8 weeks after baseline)

  • Dropout rate

    number of dropouts / total number of enrolled participants

    T1 (8 weeks after baseline)

  • Dropout reasons

    structured categories and free text

    T1 (8 weeks after baseline)

Secondary Outcomes (6)

  • Change in self-efficacy, measured by SWE (a German scale for generalized self-efficacy, Schwarzer & Jerusalem, 2003)

    T0 (baseline), T1 (8 weeks after baseline)

  • Change in adapted motivation, measured by adapted FEVER (German version of URICA (University of Rhode Island Change Assessment), Hasler et al. 2003).

    T0 (baseline), T1 (8 weeks after baseline)

  • Change in Quality of Life, measured by adapted WHOQOL-BREF (World Health Organization Quality of Life - Brief Version, German, Angermeyer et al. 2000)

    T0 (baseline), T1 (8 weeks after baseline)

  • Change in Perceived Competence, measured by adapted PCS (Perceived Competence Scale, Williams & Deci, 1996)

    T0 (baseline), T1 (8 weeks after baseline)

  • Change in Knowledge concerning therapy content, measured by a self-constructed Multiple Choice Questionnaire

    T0 (baseline), T1 (8 weeks after baseline)

  • +1 more secondary outcomes

Other Outcomes (1)

  • General Feedback, measured by open-ended questions, self-constructed

    T1 (8 weeks after baseline)

Study Arms (1)

CHANGE intervention group

EXPERIMENTAL

All enrolled participants receive the 8-session modularized group psychotherapy (CHANGE) in addition to treatment-as-usual (e.g., individual psychotherapy, pharmacotherapy, occupational therapy).

Other: CHANGE - modularized group psychotherapy

Interventions

8-session (weekly, 75 min/session), modularized group psychotherapy comprising 4 modules: (1) transition-specific psychoeducation, (2) suicidality, (3) media/internet/gaming addiction, (4) communication. Delivered in groups of max. 12 participants by a psychiatrist/psychotherapist in training under supervision, in addition to treatment-as-usual.

CHANGE intervention group

Eligibility Criteria

Age18 Years - 25 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age \>=18 years and \< 26 years
  • Ability to provide written informed consent

You may not qualify if:

  • Age \< 18 years, age \>= 26 years
  • Lack of ability to provide written informed consent
  • Severe concomitant neurological or internal medical diseases
  • Severe cognitive impairment (IQ \< 80, severe learning disability, brain damage or pervasive developmental disorder)
  • Lack of eligibility for psychotherapy (e.g., insufficient language proficiency, hostile or uncooperative behavior)
  • Acute risk of self-harm or harm to others, including acute psychosis, acute mania, or acute suicidal behavior
  • Acute substance-based addiction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Max-Planck-Institute of Psychiatry

Munich, 80804, Germany

Location

Related Publications (6)

  • Angermeyer, M. C., Kilian, R., & Matschinger, H. (2000). WHOQOL-100 und WHOQOL-BREF. Handbuch für die deutschsprachige Version der WHO Instrumente zur Erfassung von Lebensqualität. Göttingen: Hogrefe.

    BACKGROUND
  • Hasler G, Klaghofer R, Buddeberg C. [The University of Rhode Island Change Assessment Scale (URICA)]. Psychother Psychosom Med Psychol. 2003 Sep-Oct;53(9-10):406-11. doi: 10.1055/s-2003-42172. German.

    PMID: 14528410BACKGROUND
  • Schwarzer, R. & Jerusalem, M. (2003). SWE. Skala zur Allgemeinen Selbstwirksamkeitserwartung [Verfahrensdokumentation, Autorenbeschreibung und Fragebogen]. In Leibniz-Institut für Psychologie (ZPID) (Hrsg.), Open Test Archive. Trier: ZPID. https://doi.org/10.23668/psycharchives.4515

    BACKGROUND
  • Westermann, R., Elke, H., Spies, K., & Trautwein, U. (1996). Identifikation und Erfassung von Komponenten der Studienzufriedenheit. Psychologie in Erziehung und Unterricht, 43(1), 1-22.

    BACKGROUND
  • Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, Boynton MH, Halko H. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017 Aug 29;12(1):108. doi: 10.1186/s13012-017-0635-3.

    PMID: 28851459BACKGROUND
  • Williams GC, Deci EL. Internalization of biopsychosocial values by medical students: a test of self-determination theory. J Pers Soc Psychol. 1996 Apr;70(4):767-79. doi: 10.1037//0022-3514.70.4.767.

    PMID: 8636897BACKGROUND

MeSH Terms

Conditions

Mental DisordersSuicidal Ideation

Condition Hierarchy (Ancestors)

SuicideSelf-Injurious BehaviorBehavioral SymptomsBehavior

Study Officials

  • Natan Yusupov, MD, PhD

    Max-Planck-Institute of Psychiatry

    PRINCIPAL INVESTIGATOR
  • Angelika Erhardt, MD, Prof.

    Max-Planck-Institute of Psychiatry

    PRINCIPAL INVESTIGATOR
  • Peter Falkai, MD, Prof.

    Max-Planck-Institute of Psychiatry

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: All eligible participants receive the modularized CHANGE group psychotherapy in addition to treatment-as-usual; there is no control or comparator arm. Outcomes are assessed before (T0) and after (T1) the 8-session intervention (single-arm, pre-post design).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 11, 2026

First Posted

August 19, 2026

Study Start

September 3, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Last Updated

August 19, 2026

Record last verified: 2026-08

Locations